Home / Stocks / Caplin Point Lab Ltd.
CAPLIPOINT

Caplin Point Lab Ltd. Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹2,084.6

Change

-0.7 (-0.03%)

Open

₹2,060.0

Prev. Close

₹2,085.3

Day High

₹2,125.0

Day Low

₹2,013.1

Volume Analysis

Traded

244,183

Delivered

78,336

Delivery %

32.08%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Strong return on equity (20.9%)
  • •Strong operating margin (35.0%)

Weaknesses (0)

No signal for this stock

Opportunities (2)

  • •Strong 3-year EPS growth (19.4%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹2,247.26 ₹2,186.13 ₹2,135.36 ₹2,074.23 ₹2,023.46 ₹1,962.33 ₹1,911.56
Fibonacci ₹2,186.13 ₹2,143.38 ₹2,116.98 ₹2,074.23 ₹2,031.48 ₹2,005.08 ₹1,962.33
Camarilla ₹2,115.37 ₹2,105.12 ₹2,094.86 ₹2,074.23 ₹2,074.34 ₹2,064.09 ₹2,053.83

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+15.88%

1 Week

-12.64%

1 Month

-6.17%

3 Months

-18.6%

6 Months

+2.79%

1 Year

+8.54%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹264.26

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

1.64%

Net margin 29.37% × asset turnover 0.05x × equity multiplier 1.12x

Company Overview

Sector

Healthcare

Market Cap

₹17,863 Cr

P/E (TTM)

25.9

ROE

20.9%

Book Value

₹513.0

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.

TopFund Analysis

Caplin Point Lab Ltd. holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 73/100. The strongest factor is Financial Strength (100/100), while Valuation (47/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (20.9%); strong operating margin (35.0%). Strong 3-year EPS growth (19.4%).

TopFund Score — Fundamentals Quality

73/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

86

Valuation

47

Cash Flow

56

Corporate Governance

71

Momentum

57

Institutional Ownership

56

Business Quality

96

Risk & Volatility

61

Liquidity

56

From Screener.in

  • +Company has reduced debt.
  • +Company is almost debt free.
  • +Company has delivered good profit growth of 21.4% CAGR over last 5 years
  • +Company's median sales growth is 19.9% of last 10 years

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Q2 FY2026-27 earnings call audio recording made available on November 12, 2026.

Investor Presentation for the Earnings Call for the Quarter and half year ended September 30, 2026

Analyst / investor Call for the quarter and half ended September 30, 2026

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 410 436 453 459 483 493 502 510 534 543 600 610 630
Expenses + 273 293 308 307 318 331 334 332 345 353 396 397 407
Operating Profit 137 142 145 152 165 162 168 178 189 190 204 213 223
OPM % 34.0% 33.0% 32.0% 33.0% 34.0% 33.0% 33.0% 35.0% 35.0% 35.0% 34.0% 35.0% 35.0%
Other Income + 21 17 17 19 21 31 26 23 30 34 28 34 33
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 12 14 16 16 17 16 17 16 18 19 19 22 23
Profit before tax 146 145 146 154 168 177 177 184 201 204 213 225 233
Tax % 20.0% 18.0% 17.0% 19.0% 22.0% 21.0% 18.0% 18.0% 20.0% 19.0% 19.0% 20.0% 22.0%
Net Profit + 116 120 121 125 131 140 145 151 160 166 173 179 182
EPS in Rs 15 15 16 16 17 18 19 20 20 22 22 23 23
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 14 17 16 16 18 13 11 11 11 10 19 20 18

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Jun 2015 Mar 2016 9m Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 252 239 402 540 649 863 1,061 1,269 1,467 1,694 1,937 2,187 2,383
Expenses + 192 175 276 345 417 603 732 874 1,025 1,142 1,287 1,422 1,553
Operating Profit 60 64 125 195 232 260 329 395 442 552 651 765 831
OPM % 24.0% 27.0% 31.0% 36.0% 36.0% 30.0% 31.0% 31.0% 30.0% 33.0% 34.0% 35.0% 35.0%
Other Income + 3 4 10 13 19 41 23 38 55 66 92 111 129
Interest 1 0 1 1 1 0 2 1 1 1 1 1 1
Depreciation 8 7 13 19 23 32 37 47 45 53 66 73 83
Profit before tax 53 60 121 188 227 269 314 386 451 564 677 803 875
Tax % 23.0% 24.0% 21.0% 23.0% 22.0% 20.0% 20.0% 20.0% 16.0% 18.0% 20.0% 19.0% —
Net Profit + 41 46 96 145 177 215 251 308 377 461 541 650 700
EPS in Rs 5 6 13 19 23 28 32 40 50 60 71 84 91
Dividend Payout % 18.0% 20.0% 12.0% 10.0% 9.0% 9.0% 9.0% 10.0% 9.0% 8.0% 8.0% 9.0% —
Sales growth 45 38 68 34 20 33 23 20 16 16 14 13 17

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 78 113 210 349 582 858 954 1,252 1,649 2,084 2,619 3,355 3,887
Borrowings + 2 2 1 1 36 113 235 219 222 219 222 221 5
Other Liabilities + 134 137 133 136 109 139 159 250 305 380 352 446 468
Total Liabilities 229 267 358 500 743 1,126 1,364 1,736 2,191 2,698 3,208 4,038 4,375
Fixed Assets + 113 144 152 169 227 272 305 287 280 453 546 580 710
CWIP 31 0 3 15 10 20 14 18 221 117 144 234 215
Investments 0 0 17 47 70 61 11 89 281 376 590 859 966
Other Assets + 85 122 186 269 436 772 1,033 1,343 1,410 1,753 1,928 2,365 2,484
Total Assets 229 267 358 500 743 1,126 1,364 1,736 2,191 2,698 3,208 4,038 4,375
Equity Capital 15 15 15 15 15 15 15 15 15 15 15 15 15

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 50 42 68 66 83 45 269 337 271 318 432 523
Cash from Investing Activity + -23 -6 -36 -69 -100 -54 -30 -377 -216 -319 -333 -582
Cash from Financing Activity + -9 -14 -7 -12 90 80 -24 -41 -28 -38 -38 -46
Net Cash Flow 19 23 25 -14 73 70 215 -81 27 -39 61 -105
Free Cash Flow 24 34 43 18 18 -32 195 246 78 173 241 275
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 103 92 73 53 54 38 102 106 81 77 86 87

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 70.62% → 70.57%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 26.11% 24.95% 24.59% 23.93% 22.48% 21.72% 21.06% 20.82% 20.81% 21.14% 21.19% 21.52%
Promoters 70.62% 70.62% 70.56% 70.56% 70.56% 70.56% 70.56% 70.57% 70.57% 70.57% 70.57% 70.57%
FII 2.84% 3.33% 3.38% 3.71% 4.86% 5.73% 6.16% 6.51% 6.58% 6.15% 5.76% 5.72%
DII 0.43% 1.08% 1.49% 1.83% 2.11% 2.0% 2.22% 2.1% 2.05% 2.14% 2.49% 2.2%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Caplin Point Lab Ltd. (this stock) 17,863 25.9 4.58 20.9%
Alivus Life Sciences Ltd 17,803 50.6 — —
Syngene International Ltd 17,935 67.5 3.7 7.78%
Pfizer Ltd 17,601 115.0 12.74 19.8%
Cohance Lifesciences Ltd 17,511 359.0 4.49 4.89%
Dr Agarwals Health Care L 17,460 97.5 7.8 6.41%
Eris Lifesciences Limited 18,448 24.7 4.45 18.7%

Which Mutual Funds Hold Caplin Point Lab Ltd.?

Frequently Asked Questions about Caplin Point Lab Ltd.

Community Sentiment

What are other investors saying about Caplin Point Lab Ltd.?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.